Correlation between Mutations in liaFSR of Enterococcus faecium and MIC of Daptomycin: Revisiting Daptomycin Breakpoints

被引:87
作者
Munita, Jose M. [1 ,2 ]
Panesso, Diana [1 ,4 ]
Diaz, Lorena [1 ,4 ]
Tran, Truc T. [1 ,5 ]
Reyes, Jinnethe [1 ,4 ]
Wanger, Audrey [8 ]
Murray, Barbara E. [3 ,6 ,7 ]
Arias, Cesar A. [1 ,3 ,4 ]
机构
[1] Univ Texas Med Sch Houston, Lab Antimicrobial Res, Houston, TX USA
[2] Univ Desarrollo, Sch Med, Clin Alemana, Santiago, Chile
[3] Ctr Study Emerging & Reemerging Pathogens, Div Infect Dis, Dept Internal Med, Houston, TX USA
[4] Univ El Bosque, Mol Genet & Antimicrobial Resistance Unit, Bogota, Colombia
[5] Univ Houston, Coll Pharm, Houston, TX 77030 USA
[6] Univ Texas Med Sch,Houston, Lab Enterococcal Res, Houston, TX USA
[7] Univ Texas Med Sch Houston, Dept Microbiol & Mol Genet, Houston, TX USA
[8] Univ Texas Med Sch,Houston, Dept Pathol & Lab Med, Houston, TX USA
关键词
ENVELOPE STRESS-RESPONSE; VANCOMYCIN-RESISTANT; STAPHYLOCOCCUS-AUREUS; IN-VITRO; SUSCEPTIBILITY; ENDOCARDITIS; INFECTIONS; FAECALIS; VIVO; EMERGENCE;
D O I
10.1128/AAC.00509-12
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Mutations in liaFSR, a three-component regulatory system controlling cell-envelope stress response, were recently linked with the emergence of daptomycin (DAP) resistance in enterococci. Our previous work showed that a liaF mutation increased the DAP MIC of a vancomycin-resistant Enterococcus faecalis strain from 1 to 3 mu g/ml (the DAP breakpoint is 4 mu g/ml), suggesting that mutations in the liaFSR system could be a pivotal initial event in the development of DAP resistance. With the hypothesis that clinical enterococcal isolates with DAP MICs between 3 and 4 mu g/ml might harbor mutations in liaFSR, we studied 38 Enterococcus faecium bloodstream isolates, of which 8 had DAP MICs between 3 and 4 mu g/ml by Etest in Mueller-Hinton agar. Interestingly, 6 of these 8 isolates had predicted amino acid changes in the LiaFSR system. Moreover, we previously showed that among 6 DAP-resistant E. faecium isolates (MICs of >4 mu g/ml), 5 had mutations in liaFSR. In contrast, none of 16 E. faecium isolates with a DAP MIC of <= 2 mu g/ml harbored mutations in this system (P < 0.0001). All but one isolate with liaFSR changes exhibited DAP MICs of >= 16 mu g/ml by Etest using brain heart infusion agar (BHIA), a medium that better supports enterococcal growth. Our findings provide a strong association between DAP MICs within the upper susceptibility range and mutations in the liaFSR system. Concomitant susceptibility testing on BHIA may be useful for identifying these E. faecium first-step mutants. Our results also suggest that the current DAP breakpoint for E. faecium may need to be reevaluated.
引用
收藏
页码:4354 / 4359
页数:6
相关论文
共 38 条
[1]  
5a.bioMerieux, 2009, ET DAPT
[2]   Management of multidrug-resistant enterococcal infections [J].
Arias, C. A. ;
Contreras, G. A. ;
Murray, B. E. .
CLINICAL MICROBIOLOGY AND INFECTION, 2010, 16 (06) :555-562
[3]   Failure of daptomycin monotherapy for endocarditis caused by an Enterococcus faecium strain with vancomycin-resistant and vancomycin-susceptible subpopulations and evidence of in vivo loss of the vanA gene cluster [J].
Arias, Cesar A. ;
Torres, Harrys A. ;
Singh, Kavindra V. ;
Panesso, Diana ;
Moore, Judson ;
Wanger, Audrey ;
Murray, Barbara E. .
CLINICAL INFECTIOUS DISEASES, 2007, 45 (10) :1343-1346
[4]   Genetic Basis for In Vivo Daptomycin Resistance in Enterococci [J].
Arias, Cesar A. ;
Panesso, Diana ;
McGrath, Danielle M. ;
Qin, Xiang ;
Mojica, Maria F. ;
Miller, Corwin ;
Diaz, Lorena ;
Tran, Truc T. ;
Rincon, Sandra ;
Barbu, E. Magda ;
Reyes, Jinnethe ;
Roh, Jung H. ;
Lobos, Elizabeth ;
Sodergren, Erica ;
Pasqualini, Renata ;
Arap, Wadih ;
Quinn, John P. ;
Shamoo, Yousif ;
Murray, Barbara E. ;
Weinstock, George M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (10) :892-900
[5]   Cotransfer of Antibiotic Resistance Genes and a hylEfm-Containing Virulence Plasmid in Enterococcus faecium [J].
Arias, Cesar A. ;
Panesso, Diana ;
Singh, Kavindra V. ;
Rice, Louis B. ;
Murray, Barbara E. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (10) :4240-4246
[6]   Antibiotic-Resistant Bugs in the 21st Century -- A Clinical Super-Challenge. [J].
Arias, Cesar A. ;
Murray, Barbara E. .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (05) :439-443
[7]   Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America [J].
Boucher, Helen W. ;
Talbot, George H. ;
Bradley, John S. ;
Edwards, John E., Jr. ;
Gilbert, David ;
Rice, Louis B. ;
Scheld, Michael ;
Spellberg, Brad ;
Bartlett, John .
CLINICAL INFECTIOUS DISEASES, 2009, 48 (01) :1-12
[8]   The VraS/VraR two-component regulatory system required for oxacillin resistance in community-acquired methicillin-resistant Staphylococcus aureus [J].
Boyle-Vavra, Susan ;
Yin, Shaohui ;
Daum, Robert S. .
FEMS MICROBIOLOGY LETTERS, 2006, 262 (02) :163-171
[9]   A potential role for daptomycin in enterococcal infections: what is the evidence? [J].
Canton, Rafael ;
Ruiz-Garbajosa, Patricia ;
Chaves, Ricardo L. ;
Johnson, Alan P. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2010, 65 (06) :1126-1136
[10]   Daptomycin dose-effect relationship against resistant gram-positive organisms [J].
Cha, R ;
Grucz, RG ;
Rybak, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (05) :1598-1603